Literature DB >> 22890580

Cognitive testing in the diagnosis of parkinsonian disorders: a critical appraisal of the literature.

Will Lee1, David R Williams, Elsdon Storey.   

Abstract

A number of cognitive abnormalities have been identified as putative diagnostic markers in neurodegenerative parkinsonism based on statistically significant differences between diseases. The effect sizes of these differences frequently have not been reported, making practical interpretation of the results difficult. The objective of this study was to assess the potential contribution of cognitive testing to the diagnosis of parkinsonian disorders by quantifying effect size of previously identified significant differentiating cognitive features. A Medline search identified 1038 articles. Nineteen studies directly comparing at least 2 of Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, and corticobasal syndrome/degeneration were selected. Cohen's d and positive likelihood ratio were calculated as appropriate for cognitive tests showing statistically significant differences between diseases. Clinically useful differences were considered present when Cohen's d > 1 or the positive likelihood ratio > 2 and were considered high when Cohen's d > 1.94 or the positive likelihood ratio > 10. Only 16 of 141 cognitive tests were found to be highly useful. Cognitive testing was only moderately helpful in separating Parkinson's disease and multiple system atrophy. Inferior performance on phonemic (d = 1.56-2.13) and semantic (d = 1.43-2.13) verbal fluency, the Trail-Making Test (d = 1.63-1.95) and the Wisconsin Card Sorting Test (d = 1.63-2.22) were moderately to very useful in separating progressive supranuclear palsy from Parkinson's disease and multiple system atrophy. Cognitive testing could not differentiate corticobasal syndrome from other parkinsonian disorders, although sequential orobuccal apraxia was very useful (d = 2.01-2.23). Few of the cognitive tests separating parkinsonian disorders identified from previous studies have sufficient effect size to be practically useful. Even these features must be interpreted in conjunction with other clinical characteristics to be helpful diagnostically. © 2012 Movement Disorder Society.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Year:  2012        PMID: 22890580     DOI: 10.1002/mds.25113

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  5 in total

1.  Standardization and normative data obtained in the Italian population for a new verbal fluency instrument, the phonemic/semantic alternate fluency test.

Authors:  Alberto Costa; Eriola Bagoj; Marco Monaco; Silvia Zabberoni; Salvatore De Rosa; Anna Maria Papantonio; Ciro Mundi; Carlo Caltagirone; Giovanni Augusto Carlesimo
Journal:  Neurol Sci       Date:  2013-08-21       Impact factor: 3.307

2.  Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease.

Authors:  Eleonora Fiorenzato; Angelo Antonini; Valeria Camparini; Luca Weis; Carlo Semenza; Roberta Biundo
Journal:  J Neural Transm (Vienna)       Date:  2019-08-20       Impact factor: 3.575

3.  Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis.

Authors:  Eleonora Del Prete; Luca Tommasini; Sonia Mazzucchi; Daniela Frosini; Giovanni Palermo; Riccardo Morganti; Cristina Pagni; Gloria Tognoni; Ubaldo Bonuccelli; Roberto Ceravolo
Journal:  Neurol Sci       Date:  2020-08-27       Impact factor: 3.307

4.  Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.

Authors:  Eleonora Fiorenzato; Luca Weis; Cristian Falup-Pecurariu; Stefania Diaconu; Chiara Siri; Elisa Reali; Gianni Pezzoli; Patrizia Bisiacchi; Angelo Antonini; Roberta Biundo
Journal:  J Neural Transm (Vienna)       Date:  2016-06-22       Impact factor: 3.575

5.  Cognitive Profile and Its Evolution in a Cohort of Multiple System Atrophy Patients.

Authors:  Luisa Sambati; Giovanna Calandra-Buonaura; Giulia Giannini; Ilaria Cani; Federica Provini; Roberto Poda; Federico Oppi; Michelangelo Stanzani Maserati; Pietro Cortelli
Journal:  Front Neurol       Date:  2020-11-23       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.